Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12879701 | 0.88 | MAP3K12 (0.42) | SYKMAP3K12PIK3CDPIK3R1CHRNA7 | |
| SCHEMBL12892310 | 0.84 | CHRNA7 (0.49) | CHRNA7KCNH2 | |
| SCHEMBL25900772 | 0.76 | MAP3K12 (0.38) | SYKMAP3K12KCNH2CHRNB2CHRNA4 | |
| SCHEMBL1898615 | 0.75 | MAP3K12 (0.42) | SYKMAP3K12KCNH2CHRNB2CHRNA4 | |
| SCHEMBL1892540 | 0.75 | MAP3K12 (0.42) | SYKMAP3K12KCNH2CHRNB2CHRNA4 | |
| SCHEMBL1896831 | 0.75 | MAP3K12 (0.42) | SYKMAP3K12KCNH2CHRNB2CHRNA4 | |
| SCHEMBL12879194 | 0.75 | MAP3K12 (0.39) | MAP3K12PIK3CDPIK3R1HDAC1CHRNB2 | |
| SCHEMBL19368143 | 0.74 | MAP3K12 (0.39) | SYKMAP3K12CHRNA7KCNH2 | |
| SCHEMBL1200343 | 0.74 | GPR119 (0.49) | HDAC1 | |
| SCHEMBL12193332 | 0.73 | HDAC4 (0.33) | HDAC1CHRNA7CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110038876-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS | SCHERING CORPORATION | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110038876-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS | MAPK1, MAPK4, MAPK10 | SYK 423/4885MAP3K12 34/4885PIK3CD 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.